The COVID-19 Therapeutics Working Group recently completed a series of updates which we encourage all clinicians to review.
A reminder that from 1 November 2022, eligibility for COVID-19 oral treatments has been widened so that Aboriginal and Torres Strait Islander people, aged 30 years or over, will require only 1 risk factor instead of 2.
To support prompt treatment of patients as of 1 November 2022, medical practitioners and nurse practitioners will be able to add Lagevrio® and Paxlovid® to their Prescriber Bag supplies.